Tomoxetine Chloride API

Name	Tomoxetine Chloride
Chinese name	盐酸托莫西汀
Cas Number	82248-59-7
Source	India
Qualifications	USDMF/-/-/-/-

The original research was Eli Lilly and was launched in the United States in 2002. It is the only non-central stimulant approved by the FDA for the treatment of ADHD. Tomoxetine's sales in 2016 were US$855 million, an increase of 14.30% year-on-year. Tomoxetine hydrochloride can inhibit the norepinephrine and dopamine transporters in the brain, increase the level of norepinephrine in the synaptic space, and can effectively control the symptoms of ADHD, improve concentration, and has less side effects and better tolerance. Tomoxetine hydrochloride capsules were approved for marketing in China in 2016, and the oral solution was included in the priority review by the China Medical Products Administration and approved for marketing in 2018. Tomoxetine is the first-line treatment for ADHD, and it is recommended in the "Guidelines for Prevention and Treatment of Attention Deficit Hyperactivity Disorder in China", and is included in the 2017 "China Medical Insurance Drug List". With the increase of human investment in health, it will drive the growth of the ADHD market.

Hot Tags: tomoxetine chloride api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Letrozole API, Pleasant API, Fulvestrant API, Dapoxetine API, Salmeterol Xinafoate API, Lapatinib Ditosylate API

• Previous: Lanthanum Carbonate API
• Next: Rotigotine/Rotigotine API